talotrexin

Small moleculeexperimental

Clinical trial activity

5 trials · 5 clinical orgs · 0 marketing orgs

Phase 1
5
Phase 2
2
Phase 3
0
Phase 4
0

Earliest trial started Mar 1, 2004 (NCT00088023)

Timeline

2000s

  1. Jan 1, 2004

    Earliest Phase 1 Sponsor(trial)

Indications

Approved for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

Nc1nc(N)c2nc(CNc3ccc(C(=O)N[C@@H](CCCNC(=O)c4ccccc4C(=O)O)C(=O)O)cc3)cnc2n1
Mol. weight
573.57 g/mol
Lipinski Ro5
3 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • n(alpha)-(4-amino-4-deoxypteroyl)-n(delta)-hemiphthaloyl-l-ornithine
  • pt523
  • pt 523
  • pt-523
  • pt-523
  • pt-523
  • pt-523
  • talotrexin
  • talotrexin
  • talotrexin
  • talotrexin
  • talotrexin ammonium
  • talotrexin ammonium
  • talotrexin ammonium

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT00112060Phase 1/Phase 2 (Phase 2)Apr 1, 2008Spectrum Pharmaceuticals
NCT00458744Phase 1Feb 1, 2007Indiana University, National Cancer Institute (NCI), Tata Memorial Hospital
NCT00129558Phase 1/Phase 2 (Phase 2)Jul 1, 2005Spectrum Pharmaceuticals
NCT00098514Phase 1Oct 1, 2004Harvard University, National Cancer Institute (NCI)
NCT00088023Phase 1Mar 1, 2004Harvard University, National Cancer Institute (NCI), Spectrum Pharmaceuticals
Showing 5 of 5 trials
Page 1 / 1

Organizations

Research & Development (5)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
National Cancer Institute (NCI)Government3112004
Spectrum PharmaceuticalsFor profit3322004
Harvard UniversityAcademic/Hospital2112004
Indiana UniversityAcademic/Hospital1012007
Tata Memorial HospitalAcademic/Hospital1012007
5 organizations
Page 1 / 1